In the future, we are anticipating that targeted therapies will also include epigenetically inactivated tumour suppressors by, e.g., the CRISPR-dCas9 technique and viral application of epigenetic editors to reactivate not only ZAR1 in vivo in cancer. This evidence concerns the gene ZAR1 and neoplasm.